Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute for Health and Care Excellence ruled that the drug was not a cost-effective treatment for skin cancer (Press release, PharmaTimes, OCT 13, 2017, View Source [SID1234520892]).